Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified.

Serebruany VL.

Thromb Haemost. 2011 May;105(5):752-9. doi: 10.1160/TH10-12-0807. Epub 2011 Mar 8.

PMID:
21384079
3.
4.

Mortality in the TRACER and ATLAS ACS 2 trials: two more reasons to audit vital records in PLATO.

Serebruany VL, DiNicolantonio JJ, Can MM.

Cardiology. 2012;123(1):11-4. doi: 10.1159/000342085. Epub 2012 Aug 31.

PMID:
22948615
6.

Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.

Varenhorst C, Alström U, Scirica BM, Hogue CW, Åsenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C.

J Am Coll Cardiol. 2012 Oct 23;60(17):1623-30. doi: 10.1016/j.jacc.2012.07.021. Epub 2012 Sep 26.

7.

Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: challenging PLATO mortality rates.

DiNicolantonio JJ, Can MM, Serebruany VL.

Int J Cardiol. 2013 Apr 15;164(3):255-8. doi: 10.1016/j.ijcard.2012.09.113. Epub 2012 Oct 12.

PMID:
23068568
8.

The TRITON versus PLATO trials: differences beyond platelet inhibition.

Serebruany VL.

Thromb Haemost. 2010 Feb;103(2):259-61. doi: 10.1160/TH09-10-0695. Epub 2009 Dec 18.

PMID:
20024505
9.

Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.

Husted S.

Postgrad Med. 2011 Nov;123(6):79-90. doi: 10.3810/pgm.2011.11.2498. Review.

PMID:
22104457
10.

Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial.

DiNicolantonio JJ, Tomek A.

Int J Cardiol. 2013 Oct 9;168(4):4076-80. doi: 10.1016/j.ijcard.2013.07.020. Epub 2013 Aug 1.

PMID:
23911266
11.

Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor.

Serebruany VL.

Cardiology. 2010;117(3):231-3. doi: 10.1159/000322789. Epub 2011 Jan 5.

PMID:
21212672
12.

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.

Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003.

PMID:
19332184
13.

Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.

Cowper PA, Pan W, Anstrom KJ, Kaul P, Wallentin L, Davidson-Ray L, Nikolic E, Janzon M, Levin LÅ, Cannon CP, Harrington RA, Mark DB.

J Am Coll Cardiol. 2015 Feb 10;65(5):465-76. doi: 10.1016/j.jacc.2014.11.034.

14.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.

Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L.

J Am Coll Cardiol. 2011 Feb 8;57(6):672-84. doi: 10.1016/j.jacc.2010.10.029. Epub 2010 Dec 30.

15.

Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.

Serebruany VL, DiNicolantonio JJ.

Thromb Haemost. 2013 Jul;110(1):5-10. doi: 10.1160/TH13-02-0142. Epub 2013 Jun 7.

PMID:
23743577
16.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
17.

Mortality after clopidogrel in the non-invasive PLATO cohort and TRILOGY ACS trial: another mismatched death paradox.

Serebruany VL, DiNicolantonio JJ, Can MM, Dukhanin A, Tomek A.

Int J Cardiol. 2013 Sep 30;168(2):640-2. doi: 10.1016/j.ijcard.2013.05.066. Epub 2013 Jun 2.

PMID:
23735342
18.

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.

James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L.

Circulation. 2010 Sep 14;122(11):1056-67. doi: 10.1161/CIRCULATIONAHA.109.933796. Epub 2010 Aug 30.

19.

Exploring the ticagrelor-statin interplay in the PLATO trial.

Dinicolantonio JJ, Serebruany VL.

Cardiology. 2013;124(2):105-7. doi: 10.1159/000346151. Epub 2013 Feb 7.

PMID:
23407140

Supplemental Content

Support Center